Platelet refractoriness can represent a significant clinical problem that complicates the
provision of platelet transfusions, is associated with adverse clinical outcomes and …

Approximately five decades ago, alloimmunization to human leukocyte antigens (HLA) and
platelet refractoriness were recognized as potentially serious complications of platelet …

Background & Aims Patients with thrombocytopenia and chronic liver disease (CLD) may
require platelet transfusions before scheduled procedures to decrease risk of bleeding. We …

Thrombocytopenia and platelet dysfunction contribute to hemorrhagic complications in the
myelodysplastic syndromes (MDS). Reliable data regarding the frequency and …

Despite significant advancements in the production of platelet products, storage, and
transfusion, transfusion refractoriness remains a significant clinical problem, affecting up to …

An optimal platelet-count threshold for prophylactic platelet transfusion in hematopoietic
stem cell transplant (HSCT) recipients has yet to be determined. Between July 1997 and …

BACKGROUND: Lack of adequate post-transfusion platelet count increments-platelet
refractoriness-is a complication of chronic platelet support shown by 5-15% of chronic …

Patients with hypoproliferative thrombocytopenia are at an increased risk for hemorrhage
and alloimmunization to platelets. Updated guidance for optimizing platelet transfusion …

BACKGROUND Platelet transfusion–refractoriness is a challenging and expensive clinical
scenario seen most often in patients with hematologic malignancies. Although the majority of …

Platelet transfusion refractoriness due HLA alloimmunization presents a significant medical
problem, particularly among multiply transfused patients with hematologic malignancies and …